Functional imaging of SDHx-related head and neck paragangliomas: Comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I- metaiodobenzylguanidine scintigraphy, and 111in-pentetreotide scintigraphy

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2779-2785

  King, Kathryn S ^a   Chen, Clara C ^b   Alexopoulos, Dimitrios K ^b   Whatley, Millie A ^b   Reynolds, James C ^b   Patronas, Nicholas ^b   Ling, Alexander ^b   Adams, Karen T ^a   Xekouki, Paraskevi ^a,b   Lando, Howard ^c   Stratakis, Constantine A ^a,b   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Medical Specialists of Northern Virginia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; FLUORODOPAMINE F 18; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FUNCTIONAL ANATOMY; GENE MUTATION; GENETIC VARIABILITY; HEAD AND NECK PARAGANGLIOMA; HEAD AND NECK TUMOR; HUMAN; INTERMETHOD COMPARISON; MALE; PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR SCINTISCANNING; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; ADULT; BRAIN MAPPING; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SOMATOSTATIN; SUCCINATE DEHYDROGENASE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 80052545178     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0333     Document Type: Article

References (39)

1. Gujrathi C.S., Donald P.J. 2005 Current trends in the diagnosis and management of head and neck paragangliomas. Curr Opin Otolaryngol Head Neck Surg 13:339-342 (Pubitemid 41683152)
2. Erickson D., Kudva Y.C., Ebersold M.J., Thompson G.B., Grant C.S., Van Heerden J.A., Young Jr W.F. 2001 Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86:5210-5216 (Pubitemid 33070237)
3. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., Drovdlic C.M., Savul S.A., McLeod D.R., Yee H.A., Brackmann D.E., Slattery 3rd W.H., Myers E.N., Ferrell R.E., Rubinstein W.S. 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183 (Pubitemid 34252553)
4. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., Hoegerle S., Boedeker C.C., Opocher G., Schipper J., Januszewicz A., Eng C. 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951
5. Pacak K., Eisenhofer G., Goldstein D.S. 2004 Functional imaging of endocrine tumors: Role of positron emission tomography. Endocr Rev 25:568-580 (Pubitemid 39096071)
6. Fiebrich H.B., Brouwers A.H., Kerstens M.N., Pijl M.E., Kema I.P., De Jong J.R., Jager P.L., Elsinga P.H., Dierckx RA, vanderWal JE, Sluiter WJ, deVries EG, Links TP 2009 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metai-odobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 94:3922-3930
7. Koopmans K.P., Jager P.L., Kema I.P., Kerstens M.N., Albers F., Dullaart R.P. 2008 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232-1237
8. Hoegerle S., Ghanem N., Altehoefer C., Schipper J., Brink I., Moser E., Neumann H.P. 2003 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689-694 (Pubitemid 36612951)
9. Hoegerle S., Nitzsche E., Altehoefer C., Ghanem N., Manz T., Brink I., Reincke M., Moser E., Neumann H.P. 2002 Pheochromocytomas: Detection with 18F DOPA whole body PET-initial results. Radiology 222:507-512 (Pubitemid 34106126)
10. Mann G.N., Link J.M., Pham P., Pickett C.A., Byrd D.R., Kinahan P.E., Krohn K.A., Mankoff D.A. 2006 [(11)C]metahydroxyephedrine and [(18)f]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13:187-197 (Pubitemid 43157413)
11. Bhatia K.S., Ismail M.M., Sahdev A., Rockall A.G., Hogarth K., Canizales A., Avril N., Monson J.P., Grossman A.B., Reznek R.H. 2008 123I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69:181-188 (Pubitemid 352009037)
12. Esfandiari N.H., Shulkin B.L., Bui C., Jaffe C.A. 2006 Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med 31:822-825 (Pubitemid 44789571)
13. Chrisoulidou A., Kaltsas G., Ilias I., Grossman A.B. 2007 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569-585 (Pubitemid 350074048)
14. Meyer-Rochow G.Y., Schembri G.P., Benn D.E., Sywak M.S., Delbridge L.W., Robinson B.G., Roach P.J., Sidhu S.B. 2010 The utility of metaiodobenzylguanidine single photon emission computed tomography/ computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 17:392-400
15. Timmers H.J., Chen C.C., Carrasquillo J.A., Whatley M., Ling A., Havekes B., Eisenhofer G., Martiniova L., Adams K.T., Pacak K. 2009 Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757-4767
16. Linnoila R.I., Keiser H.R., Steinberg S.M., Lack E.E. 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180 (Pubitemid 20382001)
17. Timmers H.J., Kozupa A., Chen C.C., Carrasquillo J.A., Ling A., Eisenhofer G., Adams K.T., Solis D., Lenders J.W., Pacak K. 2007 Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB associated pheochromocytoma and paraganglioma. J Clin Oncol 25:2262-2269 (Pubitemid 46954653)
18. Pauwels E.K., Sturm E.J., Bombardieri E., Cleton F.J., Stokkel M.P. 2000 Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126:549-559
19. Kayani I., Groves A.M. 2006 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 6:240-244 (Pubitemid 43954019)
20. Sisson J.C., Wieland D.M. 1986 Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1:96-103 (Pubitemid 17188385)
21. Glowniak J.V., Kilty J.E., Amara S.G., Hoffman B.J., Turner F.E. 1993 Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 34:1140-1146 (Pubitemid 23191332)
22. Havekes B., King K., Lai E.W., Romijn J.A., Corssmit E.P., Pacak K. 2010 New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 72:137-145
23. Pearse A.G. 1980 The APUD concept and hormone production. Clin Endocrinol Metab 9:211-222 (Pubitemid 10005339)
24. Reubi J.C., Waser B., Khosla S., Kvols L., Goellner J.R., Krenning E., Lamberts S. 1992 In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74:1082-1089
25. Krenning E.P., Bakker W.H., Kooij P.P., Breeman W.A., Oei H.Y., De Jong M., Reubi J.C., Visser T.J., Bruns C., Kwekkeboom D.J. 1992 Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine- 123-Tyr-3-octreotide. J Nucl Med 33:652-658
26. Mackenzie I.S., Gurnell M., Balan K.K., Simpson H., Chatterjee K., Brown M.J. 2007 The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 157:533-537 (Pubitemid 350018459)
27. Brink I., Schaefer O., Walz M., Neumann H.P. 2006 Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med 31:39-41 (Pubitemid 43011938)
28. Taieb D., Tessonnier L., Sebag F., Niccoli-Sire P., Morange I., Colavolpe C., De Micco C., Barlier A., Palazzo F.F., Henry J.F., Mundler O. 2008 The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf) 69:580-586
29. Shulkin B.L., Thompson N.W., Shapiro B., Francis I.R., Sisson J.C. 1999 Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy- D-glucose PET. Nucl Med 212:35-41 (Pubitemid 29302508)
30. Taïeb D., Sebag F., Barlier A., Tessonnier L., Palazzo F.F., Morange I., Niccoli-Sire P., Fakhry N., De Micco C., Cammilleri S., Enjalbert A., Henry J.F., Mundler O. 2009 18F-FDG avidity of pheochromocytomas and paragangliomas: A new molecular imaging signature? J Nucl Med 50:711-717
31. Kaltsas G., Korbonits M., Heintz E., Mukherjee J.J., Jenkins P.J., Chew S.L., Reznek R., Monson J.P., Besser G.M., Foley R., Britton K.E., Grossman A.B. 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895-902 (Pubitemid 32207512)
32. Ilias I., Chen C.C., Carrasquillo J.A., Whatley M., Ling A., Lazúrová I., Adams K.T., Perera S., Pacak K. 2008 Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111inpentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49:1613-1619
33. Van der Harst E., De Herder W.W., Bruining H.A., Bonjer H.J., De Krijger R.R., Lamberts S.W., Van de Meiracker A.H., Boomsma F., Stijnen T., Krenning E.P., Bosman F.T., Kwekkeboom D.J. 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693 (Pubitemid 32207482)
34. Muros M.A., Llamas-Elvira J.M., Rodríguez A., Ramírez A., Gómez M., Arráez M.A., Valéncia E., Vílchez R. 1998 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun 19:735-742 (Pubitemid 28407504)
35. Whiteman M.L., Serafini A.N., Telischi F.F., Civantos F.J., Falcone S. 1997 111In octreotide scintigraphy in the evaluation of head and neck lesions. AJNR Am J Neuroradiol 18:1073-1080 (Pubitemid 30412128)
36. Kwekkeboom D.J., Van Urk H., Pauw B.K., Lamberts S.W., Kooij P.P., Hoogma R.P., Krenning E.P. 1993 Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34:873-878 (Pubitemid 23174602)
37. Milardovic R., Corssmit E.P., Stokkel M. 2010 Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 91:94-100
38. Peter D., Liu Y., Sternini C., De Giorgio R., Brecha N., Edwards R.H. 1995 Differential expression of two vesicular monoamine transporters. J Neurosci 15:6179-6188
39. Fottner C., Helisch A., Anlauf M., Rossmann H., Musholt T.J., Kreft A., Schadmand-Fischer S., Bartenstein P., Lackner KJ, Klo? ppel G, Schreckenberger M, Weber MM 2010 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl- guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 95:2800-2810